Messenger RNA Archives

How Can We Engage Patients and Physicians in the “Next Big Thing?”

Annual Reports, Antimicrobials, April 2022, Caregivers, Coronavirus Disease (COVID-19) Pandemic, Digital therapeutics, Doctors, HCPs, Issue Archives, Marketing & Advertising, Med Ad News, Messenger RNA, Patients, Physicians, Sander Flaum Column

Looking past COVID, the medical world is in turmoil. It’s hard enough for us in manufacturing and marketing to keep up with innovative technologies. Patients and caregivers have it especially tough since they are on the brunt end of disruptive innovations. Every day, patients face a ceaseless onslaught of sort of truths, half-truths, and flat-out lies about their healthcare, and HCPs no sooner graduate from med school than they discover much of their training is obsolete. Flaum Navigators Principal Sander A. Flaum explores how we can engage patients and physicians in the “Next Big Thing.”

May 2, 2022/by Andrew Humphreys

Moderna completes filing process for full approval of COVID-19 vaccine

COVID vaccine mandates, Covid-19 Data, Full Approval, Health Officials, Immune Response, Messenger RNA, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Priority Review Status

Moderna Inc. completed the real-time review process needed for a full approval for the company’s Covid-19 vaccine in people aged 18 years and older.

August 25, 2021/by Andrew Humphreys

CureVac-GSK coronavirus variant vaccine generates good immune response in rats

COVID-19 Vaccinations, Covid-19 Variants, CureVac, GlaxoSmithKline, Immune Response, Messenger RNA, R&D

A second-generation Covid-19 vaccine developed by CureVac and GlaxoSmithKline – designed to protect against coronavirus variants – produced a high level of immune response in a trial in rats, the companies said on May 13.

May 13, 2021/by Andrew Humphreys

New antibody drug helps patients breathe; virus may insert genetic fragments into genetic code

Antibody Drugs, Business, Cleveland Clinic, Coronavirus Disease 2019 (COVID-19), COVID-19 Studies, Genetic Code, Hospitalized COVID-19 Patients, Messenger RNA, Monoclonal Antibodies, Novel Coronavirus, R&D

In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, researchers found when a new monoclonal antibody drug was added to treatments being given to hospitalized Covid-19 patients who were still breathing on their own, Humanigen Inc.’s lenzilumab significantly improved their odds of not needing invasive mechanical ventilation.

May 10, 2021/by Andrew Humphreys

Flagship Pioneering Announces Launch of eRNA with Laronde

Business, Endless RNA (eRNA), Launches, Messenger RNA, Moderna, New Company, R&D, RNA Biology, Seed Funding

The world at large has become more familiar with mRNA technology due to vaccines developed against Covid-19. Now the world will be introduced to a new type of RNA-based medicine called Endless RNA, or eRNA for short.

May 10, 2021/by Andrew Humphreys

Drugmakers say Biden misguided over vaccine patent waiver

BioNTech, Business, COVID-19 Vaccines, CureVac, Joe Biden, Messenger RNA, Patents, Reuters, Supply Chain, World Trade Organisation (WTO)

Drugmakers on May 6 said U.S. President Joe Biden’s support for waiving patents of Covid-19 vaccines could disrupt a fragile supply chain and that rich countries should instead share more generously with the developing world.

May 6, 2021/by Andrew Humphreys

CureVac says well on track to request vaccine approval as planned

Business, Clinical Trials, Covid-19 Data, COVID-19 Vaccines, CureVac, Interim Analysis, Messenger RNA, R&D

Germany’s CureVac is on track to file for European approval of the company’s Covid-19 vaccine as early as this month because high infection rates among trial participants are bringing a read-out on efficacy within closer reach. The group’s late-stage trial involves more than 37,000 volunteers in Europe and Latin America, half of whom are receiving a placebo.

May 5, 2021/by Andrew Humphreys

Sanofi Acquires Tidal Therapeutics

Acquisitions, Business, CAR-T Therapy, Deals, Immune Cells, Messenger RNA, Milestone Payments, Nanoparticles, Sanofi

Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million.

April 10, 2021/by Andrew Humphreys

Money, talent flowing into mRNA sector after Covid-19 success

Messenger RNA

The success of Covid-19 vaccines based on messenger RNA (mRNA) is smoothing the way for using the novel technology not only in other vaccines, but possibly as treatments for cystic fibrosis, cancer and other hard-to-treat diseases.

March 15, 2021/by Andrew Humphreys

Tesla to Build Mobile RNA Microfactories for CureVac’s COVID-19 Vaccine

Business, Clinical Data, Clinical Trials, COVID-19 Vaccines, Facilities/Sites/Manufacturing, Messenger RNA, Mobile, Printers, R&D, RNA

Tesla, the electric car company founded and run by Elon Musk, is building mobile molecular printers to assist Germany’s CureVac in manufacturing an experimental COVID-19 vaccine.

July 2, 2020/by BioSpace